LEVELS OF MATRIX METALLOPROTEINASES IN PATIENTS WITH ISCHEMIC STROKE OF DIFFERENT ETIOLOGIES
DOI: doi.org/10.17721/1728.2748.2025.101.34-38
Keywords:
ischemic stroke, matrix metalloproteinases, proinflammatory cytokines, plasma biomarkersAbstract
Introduction. Ischemic stroke remains one of the leading causes of mortality and long-term disability worldwide. A particularly pressing issue is the differential diagnosis of its subtypes, notably cardioembolic (CE) and atherothrombotic (AT) strokes, which differ significantly in terms of pathogenesis, clinical presentation, and prognosis. The identification of biomarkers capable of reflecting stroke severity or serving as potential diagnostic indicators remains a scientific challenge. This study aimed to assess the plasma levels of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, as well as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), in patients with CE and AT stroke to evaluate their potential as differential diagnostic and prognostic markers.
Methods. The study included 122 patients with ischemic stroke admitted to the neurology department of Kyiv City Clinical Hospital No. 4 between 2016 and 2020. Based on comprehensive clinical assessment, neuroimaging, and detailed medical history, patients were categorized into two groups: those with atherothrombotic stroke (AT, n=66) and those with cardioembolic stroke (CE, n=56). A control group comprised 35 healthy individuals. Biomarker levels were measured in plasma samples using enzyme-linked immunosorbent assay (ELISA).
Results. Significantly elevated plasma levels of MMP-2, MMP-9, IL-6, and TNF-α were observed in both patient groups compared to controls (p < 0.05). Median concentrations of all four biomarkers were higher in the CE group; however, intergroup differences between CE and AT subtypes did not reach statistical significance. These findings suggest a possible association between biomarker levels and the severity of ischemic injury, though the lack of subtype specificity limits their differential diagnostic utility.
Conclusions. Matrix metalloproteinases (MMP-2 and MMP-9) and proinflammatory cytokines (IL-6 and TNF-α) demonstrate potential as biomarkers of ischemic stroke severity. Their levels are significantly elevated in the acute phase of the disease, yet they do not allow for reliable differentiation between atherothrombotic and cardioembolic subtypes. Further studies should focus on the dynamic profiling of these biomarkers in conjunction with other clinical and laboratory indicators to support personalized stroke management strategies.
References
Candelario-Jalil, E., Yang, Y., & Rosenberg, G. A. (2009). Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience, 158(3), 983–994. https://doi.org/10.1016/j.neuroscience.2008.06.025
Castellanos, M., Leira, R., Serena, J., Pumar, J. M., Lizasoain, I., Castillo, J., & Dávalos, A. (2003). Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke, 34(1), 40–46. https://doi.org/10.1161/01.str.0000046764.57344.31
Clark, A. W., Krekoski, C. A., Bou, S. S., Chapman, K. R., & Edwards, D. R. (1997). Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neuroscience letters, 238(1-2), 53–56. https://doi.org/10.1016/s0304-3940(97)00859-8
GBD 2019 Stroke Collaborators. (2021). Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology, 20(10), 795 – 820. https://doi.org/10.1016/S1474-4422(21)00252-0
Griñán, K., Arboix, A., Massons, J., Díez, L., Vergés, E., Gil, F., Arboix-Alió, J., Sánchez-López, M. J., & García-Eroles, L. (2021). Cardioembolic stroke: Risk factors, clinical features, and early outcome in 956 consecutive patients. Revista de Investigación Clínica, 73(1), 23-30. https://doi.org/10.24875/ric.20000227
Lakhan, S. E., Kirchgessner, A., & Hofer, M. (2009). Inflammatory mechanisms in ischemic stroke: therapeutic approaches. Journal of translational medicine, 7, 97. https://doi.org/10.1186/1479-5876-7-97
Li, X., Lin, S., Chen, X., Huang, W., Li, Q., Zhang, H., Chen, X., Yang, S., Jin, K., & Shao, B. (2019). The prognostic value of serum cytokines in patients with acute ischemic stroke. Aging and Disease, 10(3), 544–556. https://doi.org/10.14336/AD.2018.0820
Lo, E. H. (2008). A new penumbra: Transitioning from injury into repair after stroke. Nature Medicine, 14, 497–500. https://doi.org/10.1038/nm1735
Magnoni, S., Baker, A., George, S. J., Duncan, W. C., Kerr, L. E., McCulloch, J., & Horsburgh, K. (2004). Differential alterations in the expression and activity of matrix metalloproteinases 2 and 9 after transient cerebral ischemia in mice. Neurobiology of disease, 17(2), 188–197. https://doi.org/10.1016/j.nbd.2004.07.020
Ormstad, H., Aass, H. C., Lund-Sørensen, N., Amthor, K. F., & Sandvik, L. (2011). Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. Journal of neurology, 258(4), 677–685. https://doi.org/10.1007/s00415-011-6006-0
Pawluk, H., Woźniak, A., Tafelska-Kaczmarek, A., Kosinska, A., Pawluk, M., Sergot, K., Grochowalska, R., & Kołodziejska, R. (2025). The Role of IL-6 in Ischemic Stroke. Biomolecules, 15(4), 470. https://doi.org/10.3390/biom15040470
Prokopiv, M. M., Okuneva, S.-M. S., Heletiuk, Y. L., Fartushna, O. Y., & Symonenko, G. G. (2024). The influence of the war events on the epidemiology of cerebrovascular diseases and strokes among residents of Kyiv, Ukraine. International Neurological Journal, 20(7), 394–399. https://doi.org/10.22141/2224-0713.20.7.2024.1119
Ramos-Fernandez, M., Bellolio, M. F., & Stead, L. G. (2011). Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 20(1), 47–54. https://doi.org/10.1016/j.jstrokecerebrovasdis.2009.10.008
Smith, C. J., Emsley, H. C. A., Gavin, C. M., Georgiou, R. F., Vail, A., Barberan, E. M., del Zoppo, G. J., Hallenbeck, J. M., Rothwell, N. J., Hopkins, S. J., & Tyrrell, P. J. (2004). Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurology, 4, Article 2. https://doi.org/10.1186/1471-2377-4-2
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., Commodore-Mensah, Y., Elkind, M. S. V., Evenson, K. R., Eze-Nliam, C., Fugar, S., Generoso, G., Heard, D. G., Hiremath, S., Ho, J. E., Kalani, R., Kazi, D. S., Ko, D., Levine, D. A., Liu, J., Ma, J., Magnani, J. W., Michos, E. D., Mussolino, M. E., Navaneethan, S. D., Parikh, N. I., Poudel, R., Rezk-Hanna, M., Roth, G. A., Shah, N. S., St-Onge, M. P., Thacker, E. L., Virani, S. S., Voeks, J. H., Wang, N. Y., Wong, N. D., Wong, S. S., Yaffe, K., Martin, S. S., & American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. (2023). Heart disease and stroke statistics—2023 update: A report from the American Heart Association. Circulation, 147(8), e93–e621.
Turner, R. J., & Sharp, F. R. (2016). Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke. Frontiers in Cellular Neuroscience, 10, Article 56. https://doi.org/10.3389/fncel.2016.00056
Zhu, H., Hu, S., Li, Y., Sun, Y., Xiong, X., Hu, X., Chen, J., & Qiu, S. (2022). Interleukins and ischemic stroke. Frontiers in Immunology, 13, 828447. https://doi.org/10.3389/fimmu.2022.828447
